Cabotegravir/rilpivirine (Cabenuva) vs Tenofovir alafenamide/emtricitabine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Cabotegravir/rilpivirine (Cabenuva)

Marketed by GlaxoSmithKline

Approved in HIVsmall molecule
Weak signal

NCT05917509 · Phase 3 · completed

The 171 participants were assigned to active treatment groups without randomization or blinding, which limits the reliability of comparisons between the regimens. The primary outcomes measured virologic suppression. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: March 2027 · NCT06411223 (registry estimate)

Reported efficacy

Percentage of Participants With Plasma Human Immunodeficiency Virus-ribonucleic Acid (HIV-RNA) >=50 Copies Per Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Algorithm at Week 48: HIV-1 RNA >=50 copies/mL (FDA Snapshot) at Week 48, cabotegravir LA + rilpivirine LA every 8 weeks vs every 4 weeks: 1.7% vs 1.0%, adjusted difference 0.8% (95% CI -0.6 to 2.2); non-inferior against the 4% margin (CT.gov posted results). (met)

Result source: NCT03299049

Tenofovir alafenamide/emtricitabine · Descovy

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Reliable signal

NCT02121795 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial of 668 participants, with 333 receiving F/TAF and 330 receiving FTC/TDF in the treated analysis. The primary clinical endpoint was met: virologic suppression was 94.3% versus 93.0%, and the prespecified non-inferiority confidence interval remained within the 10% margin.

Next expected readout: January 2027 · NCT07349758 (registry estimate)

Reported efficacy

Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Incidence of HIV-1 Infection Per 100 Person Years (PY) (When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)): Descovy (DVY) 0.16 HIV-1 infections per 100 PY (95% CI 0.064 to 0.33) | Truvada (TVD) 0.342 HIV-1 infections per 100 PY (95% CI 0.191 to 0.564) (met)

Result source: NCT02842086

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCabotegravir/​rilpivirine (Cabenuva)Tenofovir alafenamide/​emtricitabine
HIV-1 RNA below 50 copies/mL (week 48)94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
94.3% vs 93%vs FTC/TDFwk 48 · n 333NCT02121795
31 other results
  • 88.6% vs 92.4% wk 48 · n 280 · Phase 3 · primary NCT02469246
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 92.4% vs 93% wk 48 · n 314 · Phase 3 · primary NCT02607930
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.4% vs 97.8% wk 24 · n 183 · Phase 3 · primary NCT02605954
  • 96.6% vs 97.8% wk 24 · n 89 · Phase 3 · primary NCT02605954
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 88.6% vs 89.1% wk 96 · n 333 · Phase 3 · secondary NCT02121795
  • 82.1% vs 88.4% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 90.4% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 74.8% vs 74% wk 24 · n 103 · Phase 2 · primary NCT01565850
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 76.7% vs 84% wk 48 · n 103 · Phase 2 · secondary NCT01565850
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
HIV-1 RNA 50 copies/mL or more (week 48)0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT036393110.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
2 other results
  • 1.8% vs 0.7% wk 48 · n 280 · Phase 3 · secondary NCT02469246
  • 2.5% vs 1.1% wk 96 · n 280 · Phase 3 · secondary NCT02469246
CD4 count, change (week 48)270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
60 vs 42vs Baseline Treatment Regimen (SBR)wk 96 · n 959NCT01815736
36 other results
  • 50 vs 46 wk 96 · n 299 · Phase 3 · secondary NCT02121795
  • -29 vs 10 wk 96 · n 229 · Phase 3 · secondary NCT02469246
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 20 vs 21 wk 48 · n 313 · Phase 3 · secondary NCT02121795
  • -30 vs 2 wk 48 · n 249 · Phase 3 · secondary NCT02469246
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 5 vs 41 wk 48 · n 85 · Phase 3 · secondary NCT01968551
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • -28 vs 8 wk 24 · n 169 · Phase 3 · secondary NCT02605954
  • -23 vs 8 wk 24 · n 86 · Phase 3 · secondary NCT02605954
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  • 275 vs 248 wk 80 · n 48 · Phase 2 · secondary NCT04143594
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 231 vs 212 wk 48 · n 85 · Phase 2 · secondary NCT01565850
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 186 vs 139 wk 24 · n 91 · Phase 2 · secondary NCT01565850

HIV-1 RNA below 50 copies/mL (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
94% vs 91%vs CAB 30 mg+ABC/3TCIM-Q4W · wk 32 · n 115NCT02120352
125 other results
  • 95% vs 91% IM-Q8W · wk 32 · n 115 · Phase 2 · primary NCT02120352
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · primary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · primary NCT01641809
  • 67% vs 0% 30 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 30 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 73% vs 0% 30 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 72% vs 0% 30 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 67% vs 0% 30 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 75% vs 63% 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 30 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 83% 30 mg · wk 96 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 68% 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 89% 30 mg · wk 84 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 72 · n 53 · Phase 2 · secondary NCT01641809
  • 73% vs 68% 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 63% vs 0% 30 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 30 mg · wk 60 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 94% 30 mg · wk 48 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 68% 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 89% 30 mg · wk 40 · n 53 · Phase 2 · secondary NCT01641809
  • 82% vs 71% 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 30 mg · wk 36 · n 53 · Phase 2 · secondary NCT01641809
  • 80% vs 69% 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 91% vs 91% 30 mg · wk 32 · n 53 · Phase 2 · secondary NCT01641809
  • 78% vs 69% 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 89% vs 91% 30 mg · wk 28 · n 53 · Phase 2 · secondary NCT01641809
  • 75% vs 66% 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 85% vs 87% 30 mg · wk 26 · n 53 · Phase 2 · secondary NCT01641809
  • 85% vs 74% 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 94% vs 96% 30 mg · wk 24 · n 53 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 30 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 60% vs 0% 30 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 30 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 144 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 132 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 156 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 120 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 168 · n 61 · Phase 2 · secondary NCT01641809
  • 80% vs 0% 60 mg · wk 108 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 180 · n 61 · Phase 2 · secondary NCT01641809
  • 84% vs 63% 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 192 · n 61 · Phase 2 · secondary NCT01641809
  • 93% vs 83% 60 mg · wk 96 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 204 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 84 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 77% vs 0% 60 mg · wk 216 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 72 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 228 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 60 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 71% 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 240 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 94% 60 mg · wk 48 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 68% 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 89% 60 mg · wk 40 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 252 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 94% 60 mg · wk 36 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 69% 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 60 mg · wk 32 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 91% 60 mg · wk 28 · n 55 · Phase 2 · secondary NCT01641809
  • 85% vs 66% 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 95% vs 87% 60 mg · wk 26 · n 55 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 75% vs 0% 60 mg · wk 264 · n 61 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 60 mg · wk 24 · n 55 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 276 · n 61 · Phase 2 · secondary NCT01641809
  • 74% vs 0% 60 mg · wk 288 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 300 · n 61 · Phase 2 · secondary NCT01641809
  • 70% vs 0% 60 mg · wk 312 · n 61 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 144 · n 60 · Phase 2 · secondary NCT01641809
  • 62% vs 0% 10 mg · wk 132 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 156 · n 60 · Phase 2 · secondary NCT01641809
  • 65% vs 0% 10 mg · wk 120 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 168 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 0% 10 mg · wk 108 · n 60 · Phase 2 · secondary NCT01641809
  • 58% vs 0% 10 mg · wk 180 · n 60 · Phase 2 · secondary NCT01641809
  • 68% vs 63% 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 57% vs 0% 10 mg · wk 192 · n 60 · Phase 2 · secondary NCT01641809
  • 79% vs 83% 10 mg · wk 96 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 204 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 84 · n 52 · Phase 2 · secondary NCT01641809
  • 72% vs 68% 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 55% vs 0% 10 mg · wk 216 · n 60 · Phase 2 · secondary NCT01641809
  • 83% vs 89% 10 mg · wk 72 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 68% 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 228 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 89% 10 mg · wk 60 · n 52 · Phase 2 · secondary NCT01641809
  • 80% vs 71% 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 240 · n 60 · Phase 2 · secondary NCT01641809
  • 92% vs 94% 10 mg · wk 48 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 68% 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 89% 10 mg · wk 40 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 71% 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 252 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 94% 10 mg · wk 36 · n 52 · Phase 2 · secondary NCT01641809
  • 83% vs 69% 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 91% 10 mg · wk 32 · n 52 · Phase 2 · secondary NCT01641809
  • 85% vs 69% 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 91% 10 mg · wk 28 · n 52 · Phase 2 · secondary NCT01641809
  • 78% vs 66% 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 90% vs 87% 10 mg · wk 26 · n 52 · Phase 2 · secondary NCT01641809
  • 87% vs 74% 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 53% vs 0% 10 mg · wk 264 · n 60 · Phase 2 · secondary NCT01641809
  • 96% vs 96% 10 mg · wk 24 · n 52 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 276 · n 60 · Phase 2 · secondary NCT01641809
  • 50% vs 0% 10 mg · wk 288 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 300 · n 60 · Phase 2 · secondary NCT01641809
  • 52% vs 0% 10 mg · wk 312 · n 60 · Phase 2 · secondary NCT01641809
  • 98% vs 100% Q2M · wk 48 · n 90 · Phase 2 · secondary NCT03639311
Tenofovir alafenamide/​emtricitabine
94.3% vs 93%vs FTC/TDFwk 48 · n 333NCT02121795
31 other results
  • 88.6% vs 92.4% wk 48 · n 280 · Phase 3 · primary NCT02469246
  • 91.6% vs 88.5% wk 48 · n 431 · Phase 3 · primary NCT01797445
  • 92.4% vs 93% wk 48 · n 314 · Phase 3 · primary NCT02607930
  • 87.2% vs 80.8% wk 48 · n 289 · Phase 3 · primary NCT01705574
  • 93.4% vs 97.8% wk 24 · n 183 · Phase 3 · primary NCT02605954
  • 96.6% vs 97.8% wk 24 · n 89 · Phase 3 · primary NCT02605954
  • 81.5% vs 84.1% wk 144 · n 314 · Phase 3 · secondary NCT02607930
  • 88.6% vs 89.1% wk 96 · n 333 · Phase 3 · secondary NCT02121795
  • 82.1% vs 88.4% wk 96 · n 280 · Phase 3 · secondary NCT02469246
  • 84% vs 82.3% wk 96 · n 431 · Phase 3 · secondary NCT01797445
  • 92.8% vs 89.1% wk 96 · n 959 · Phase 3 · secondary NCT01815736
  • 87.9% vs 89.8% wk 96 · n 314 · Phase 3 · secondary NCT02607930
  • 93.3% vs 91.1% wk 48 · n 284 · Phase 3 · secondary NCT03110380
  • 90.4% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 84.9% vs 92% wk 54 · n 53 · Phase 2 · primary NCT04143594
  • 84.6% vs 92% wk 54 · n 52 · Phase 2 · primary NCT04143594
  • 96.9% vs 93.9% wk 24 · n 65 · Phase 2 · primary NCT02397694
  • 88.4% vs 89.7% wk 24 · n 112 · Phase 2 · primary NCT01497899
  • 74.8% vs 74% wk 24 · n 103 · Phase 2 · primary NCT01565850
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 75.5% vs 92% wk 80 · n 53 · Phase 2 · secondary NCT04143594
  • 86.5% vs 92% wk 80 · n 52 · Phase 2 · secondary NCT04143594
  • 96.9% vs 90.9% wk 48 · n 65 · Phase 2 · secondary NCT02397694
  • 88.4% vs 87.9% wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 76.7% vs 84% wk 48 · n 103 · Phase 2 · secondary NCT01565850
  • 90.4% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 88.7% vs 96% wk 38 · n 53 · Phase 2 · secondary NCT04143594
  • 88.5% vs 96% wk 38 · n 52 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594
  • 92.5% vs 100% wk 28 · n 53 · Phase 2 · secondary NCT04143594
  • 94.2% vs 100% wk 28 · n 52 · Phase 2 · secondary NCT04143594

HIV-1 RNA 50 copies/mL or more (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
0% vs 0%vs DTG + RPVQ2M · wk 48 · n 90NCT03639311
Tenofovir alafenamide/​emtricitabine
0.4% vs 1.1%vs DTG + F/TAFwk 48 · n 284NCT03110380
2 other results
  • 1.8% vs 0.7% wk 48 · n 280 · Phase 3 · secondary NCT02469246
  • 2.5% vs 1.1% wk 96 · n 280 · Phase 3 · secondary NCT02469246

CD4 count, change (week 48)

Cabotegravir/​rilpivirine (Cabenuva)
270.6 vs 369.9vs CAB 30 mg+ABC/3TCIM-Q4W · wk 96 · n 108NCT02120352
36 other results
  • 263.7 vs 346.1 IM-Q4W · wk 32 · n 108 · Phase 2 · secondary NCT02120352
  • 257.5 vs 369.9 IM-Q8W · wk 96 · n 112 · Phase 2 · secondary NCT02120352
  • 264.4 vs 346.1 IM-Q8W · wk 32 · n 112 · Phase 2 · secondary NCT02120352
  • 267.5 vs 281.7 30 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 287 vs 279.4 30 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 201.4 vs 257.1 30 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 269.4 vs 263.8 30 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 241.6 vs 262.5 30 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 212.8 vs 221.5 30 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 213 vs 185.2 30 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 205.2 vs 197.4 30 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 188.1 vs 178.2 30 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 177.7 vs 166.4 30 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 180.9 vs 143.4 30 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
  • 286.2 vs 281.7 60 mg · wk 96 · n 61 · Phase 2 · secondary NCT01641809
  • 278.1 vs 279.4 60 mg · wk 84 · n 61 · Phase 2 · secondary NCT01641809
  • 254 vs 257.1 60 mg · wk 72 · n 61 · Phase 2 · secondary NCT01641809
  • 266.1 vs 263.8 60 mg · wk 60 · n 61 · Phase 2 · secondary NCT01641809
  • 259 vs 262.5 60 mg · wk 48 · n 61 · Phase 2 · secondary NCT01641809
  • 212.3 vs 221.5 60 mg · wk 40 · n 61 · Phase 2 · secondary NCT01641809
  • 265 vs 185.2 60 mg · wk 36 · n 61 · Phase 2 · secondary NCT01641809
  • 209.9 vs 197.4 60 mg · wk 32 · n 61 · Phase 2 · secondary NCT01641809
  • 193.3 vs 178.2 60 mg · wk 28 · n 61 · Phase 2 · secondary NCT01641809
  • 194.7 vs 166.4 60 mg · wk 26 · n 61 · Phase 2 · secondary NCT01641809
  • 204 vs 143.4 60 mg · wk 24 · n 61 · Phase 2 · secondary NCT01641809
  • 269.4 vs 281.7 10 mg · wk 96 · n 60 · Phase 2 · secondary NCT01641809
  • 261.5 vs 279.4 10 mg · wk 84 · n 60 · Phase 2 · secondary NCT01641809
  • 232 vs 257.1 10 mg · wk 72 · n 60 · Phase 2 · secondary NCT01641809
  • 217.7 vs 263.8 10 mg · wk 60 · n 60 · Phase 2 · secondary NCT01641809
  • 235.1 vs 262.5 10 mg · wk 48 · n 60 · Phase 2 · secondary NCT01641809
  • 203.6 vs 221.5 10 mg · wk 40 · n 60 · Phase 2 · secondary NCT01641809
  • 192 vs 185.2 10 mg · wk 36 · n 60 · Phase 2 · secondary NCT01641809
  • 191.4 vs 197.4 10 mg · wk 32 · n 60 · Phase 2 · secondary NCT01641809
  • 205 vs 178.2 10 mg · wk 28 · n 60 · Phase 2 · secondary NCT01641809
  • 186.4 vs 166.4 10 mg · wk 26 · n 60 · Phase 2 · secondary NCT01641809
  • 172.5 vs 143.4 10 mg · wk 24 · n 60 · Phase 2 · secondary NCT01641809
Tenofovir alafenamide/​emtricitabine
60 vs 42vs Baseline Treatment Regimen (SBR)wk 96 · n 959NCT01815736
36 other results
  • 50 vs 46 wk 96 · n 299 · Phase 3 · secondary NCT02121795
  • -29 vs 10 wk 96 · n 229 · Phase 3 · secondary NCT02469246
  • 274 vs 260 wk 96 · n 369 · Phase 3 · secondary NCT01797445
  • 237 vs 281 wk 96 · n 269 · Phase 3 · secondary NCT02607956
  • 287 vs 288 wk 96 · n 276 · Phase 3 · secondary NCT02607930
  • 20 vs 21 wk 48 · n 313 · Phase 3 · secondary NCT02121795
  • -30 vs 2 wk 48 · n 249 · Phase 3 · secondary NCT02469246
  • 225 vs 200 wk 48 · n 404 · Phase 3 · secondary NCT01797445
  • 180 vs 201 wk 48 · n 290 · Phase 3 · secondary NCT02607956
  • 278 vs 289 wk 144 · n 262 · Phase 3 · secondary NCT02607956
  • 235 vs 228 wk 48 · n 294 · Phase 3 · secondary NCT02607930
  • 299 vs 317 wk 144 · n 255 · Phase 3 · secondary NCT02607930
  • 18 vs 36 wk 48 · n 262 · Phase 3 · secondary NCT03110380
  • 221 vs 212 wk 48 · n 263 · Phase 3 · secondary NCT01705574
  • 56 vs -1 wk 48 · n 102 · Phase 3 · secondary NCT02616783
  • 5 vs 41 wk 48 · n 85 · Phase 3 · secondary NCT01968551
  • 48 vs -4 wk 24 · n 99 · Phase 3 · secondary NCT02616783
  • -28 vs 8 wk 24 · n 169 · Phase 3 · secondary NCT02605954
  • -23 vs 8 wk 24 · n 86 · Phase 3 · secondary NCT02605954
  • 23 vs 12 wk 24 · n 88 · Phase 3 · secondary NCT01968551
  • 275 vs 248 wk 80 · n 48 · Phase 2 · secondary NCT04143594
  • 262 vs 248 wk 80 · n 41 · Phase 2 · secondary NCT04143594
  • 245 vs 248 wk 80 · n 46 · Phase 2 · secondary NCT04143594
  • 204 vs 193 wk 54 · n 49 · Phase 2 · secondary NCT04143594
  • 213 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 220 vs 193 wk 54 · n 47 · Phase 2 · secondary NCT04143594
  • 177 vs 204 wk 48 · n 112 · Phase 2 · secondary NCT01497899
  • 231 vs 212 wk 48 · n 85 · Phase 2 · secondary NCT01565850
  • 195 vs 232 wk 38 · n 49 · Phase 2 · secondary NCT04143594
  • 220 vs 232 wk 38 · n 51 · Phase 2 · secondary NCT04143594
  • 211 vs 232 wk 38 · n 46 · Phase 2 · secondary NCT04143594
  • 172 vs 163 wk 28 · n 49 · Phase 2 · secondary NCT04143594
  • 158 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 206 vs 163 wk 28 · n 50 · Phase 2 · secondary NCT04143594
  • 165 vs 179 wk 24 · n 112 · Phase 2 · secondary NCT01497899
  • 186 vs 139 wk 24 · n 91 · Phase 2 · secondary NCT01565850
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
6 other shared endpoints and safety

Coverage. Cabotegravir/rilpivirine (Cabenuva): 10 of 10 rows · Tenofovir alafenamide/emtricitabine: 10 of 10 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCabotegravir/​rilpivirine (Cabenuva)
Rows use multiple source trials
Tenofovir alafenamide/​emtricitabine
Rows use multiple source trials
CD4+
absolute change · cells/uL
No placebo or comparator arm
276 cells/uL @ 324wk30 mga,b,c,d,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
272 cells/uL @ 324wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
402 cells/uL @ 324wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
224 cells/uL @ 48wka,b,c,d,e
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 2 more doses
-66 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-179 cells/uL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV-1 RNA
absolute change · log
Induction
-2.634 vs -2.533 Efavirenz log @ 12wk30 mga,c,d
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
-2.79 vs -2.533 Efavirenz log @ 12wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-2.793 vs -2.533 Efavirenz log @ 12wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-3.03 vs -3.15 DTG + F/TAF log @ 12wkc,d
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA
absolute change · log
Maintenance
-2.89 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q4Wa,f,c,g
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more dose
-2.77 vs -2.77 CAB 30 mg+ABC/3TC log @ 96wkIM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
-3.08 vs -3.1 DTG + F/TAF log @ 96wkf,c,g
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1 other source trial
-3.09 vs -3.1 ABC/DTG/3TC log @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA
absolute change · log
No placebo or comparator arm
-2.215 log @ 324wk30 mga,f,c,d,e
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
-2.438 log @ 324wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-2.488 log @ 324wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
-3.04 log @ 48wkf,c,d,e
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
Induction
75% (n=60) vs 61% (n=62) Efavirenz @ 12wk30 mga,f,c,g
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
show 2 more doses
82% (n=61) vs 61% (n=62) Efavirenz @ 12wk60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
88% (n=60) vs 61% (n=62) Efavirenz @ 12wk10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
96.6% (n=89) vs 98.9% (n=91) ABC/3TC+3rd Agent @ 12wka,f,c,g
NCT02605954 · Phase 3 · registry result, not featured evidence
show 1 more dose
95.1% (n=183) vs 98.9% (n=91) ABC/3TC+3rd Agent @ 12wk
NCT02605954 · Phase 3 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies
responder rate · % of participants
No placebo or comparator arm
87% (n=430) @ 52wkc,g,h
NCT04399551 · Phase 3 · registry result, not featured evidence
81.4% (n=242) @ 144wka,c,g,h
NCT01818596 · Phase 3
show 1 more dose
100% (n=6) @ 144wk
NCT01818596 · Phase 3
Dropout rate
13.6%i
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
8.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
13.1%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
6.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
11.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
1.3%CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
15.6%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
11.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
13.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
15.2%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
11.4%F/TAF + 3rd Agentj
NCT02121795 · Phase 3 · combination
show 52 more results
—F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
—Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
—Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
23.5%F/TAF
NCT02469246 · Phase 3
—F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
—Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
—Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
20%E/C/F/TAF
NCT01797445 · Phase 3
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
5.1%E/C/F/TAF
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
12.6%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
0%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
4%Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
1.9%Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0%Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
4.4%
NCT04782180 · Phase 4 · registry result, not featured evidence
18.7%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
17.1%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
7.4%B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
5.4%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
6.6%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
5.3%E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
5.4%F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
0%Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
0%Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
—HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
—HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
9.1%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
3.3%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
8%E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
0%E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
21.2%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
34%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
30.8%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
4.6%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
5.3%
NCT01497899 · Phase 2 · registry result, not featured evidence
19.4%
NCT01565850 · Phase 2 · registry result, not featured evidence
3%
NCT03960645 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
—i
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
5.7%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
—Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
3.5%
NCT04399551 · Phase 3 · registry result, not featured evidence
4.3%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
—IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
1.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
1.7%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
4.9%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
—30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
—Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
—Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
—30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
—300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
1.5%F/TAF + 3rd Agentj
NCT02121795 · Phase 3 · combination
show 52 more results
—F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
—Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
—Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
4.2%F/TAF
NCT02469246 · Phase 3
—F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
—Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
—Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
0.7%E/C/F/TAF
NCT01797445 · Phase 3
—E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
—Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
0.7%E/C/F/TAF
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
—Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
—Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
2.8%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
0%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
—Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
—
NCT04782180 · Phase 4 · registry result, not featured evidence
1.2%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
0%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.1%B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
—Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
—DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
—Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
0.9%
NCT02616783 · Phase 3 · registry result, not featured evidence
—Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
2.7%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
—E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
—F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
—Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
—Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
—HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
—HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
—Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
—E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
—E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
1.9%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
0%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
0%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
1.5%BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
0.9%
NCT01497899 · Phase 2 · registry result, not featured evidence
0%
NCT01565850 · Phase 2 · registry result, not featured evidence
—
NCT03960645 · Phase 1 · registry result, not featured evidence
Serious AEs
0%i
NCT04982445 · Phase 4 · registry result, not featured evidence
show 45 more results
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
0%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
1.1%400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
—400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
3.6%Direct to Injections (D2I)
NCT04542070 · Phase 3 · registry result, not featured evidence
6.3%Oral lead-in Phase (OLI)
NCT04542070 · Phase 3 · registry result, not featured evidence
3.4%Q2M
NCT04542070 · Phase 3 · registry result, not featured evidence
4%
NCT04399551 · Phase 3 · registry result, not featured evidence
7.8%
NCT04001803 · Phase 3 · registry result, not featured evidence
—CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
12.7%Step 2: CAB LA + VRC07-523LS
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
10%IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
27%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
26.5%IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
11.1%Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
—30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
0%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.4%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
17%30 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.1%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.8%60 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
—10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence · pooled
3.3%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
9.6%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
15.2%10 mg
NCT01641809 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT00920426 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 1 (C1) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 2 (C2) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 3 (C3) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
12.5%Part 1: Cohort 3 (C3) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4 (C4) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 1: Cohort 4h (C4h) CAB200 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 1: Cohort 4h (C4h) CAB400 + r
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
0%Part 2: Cohort 5 (C5) CAB200
NCT04484337 · Phase 1 · registry result, not featured evidence
0%Part 2: Cohort 5 (C5) CAB400
NCT04484337 · Phase 1 · registry result, not featured evidence
0%30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence
7.1%300 mg + 30 mg
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
—F/TAF + 3rd Agentj
NCT02121795 · Phase 3 · combination
show 52 more results
8.7%F/TAF + 3rd Agent (Double-Blind)
NCT02121795 · Phase 3 · combination
6.1%Open-Label F/TAF From F/TAF
NCT02121795 · Phase 3
9.7%Open-Label F/TAF From FTC/TDF
NCT02121795 · Phase 3
—F/TAF
NCT02469246 · Phase 3
19.6%F/TAF (Double-Blind Phase)
NCT02469246 · Phase 3
0%Open-Label F/TAF From ABC/3TC
NCT02469246 · Phase 3
0%Open-Label F/TAF From F/TAF
NCT02469246 · Phase 3
—E/C/F/TAF
NCT01797445 · Phase 3
12.5%E/C/F/TAF (Double-Blind Phase)
NCT01797445 · Phase 3
2.8%Open-Label E/C/F/TAF From E/C/F/TA
NCT01797445 · Phase 3
1.7%Open-Label E/C/F/TAF From E/C/F/TD
NCT01797445 · Phase 3
—E/C/F/TAF
NCT01815736 · Phase 3
3%Extension Phase: E/C/F/TAF From E/
NCT01815736 · Phase 3
5.2%Extension Phase: E/C/F/TAF From SB
NCT01815736 · Phase 3
8.2%Randomized Phase: E/C/F/TAF
NCT01815736 · Phase 3
22.7%Cohort 1 (Treatment-experienced)
NCT01818596 · Phase 3
16.7%Cohort 2 (Treatment-naive)
NCT01818596 · Phase 3
20%Cohort 1: Age 12 to < 18 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
13.5%Cohort 2: Age 6 to < 12 Years and
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
3.7%Cohort 3: Age ≥ 2 Years and Weight
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0%
NCT04782180 · Phase 4 · registry result, not featured evidence
20%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
14%B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
7.5%B/F/TAF to B/F/TAF
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
—B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
12.7%Double-Blind Treatment Phase B/F/T
NCT03110380 · Phase 3 · registry result, not featured evidence
9.6%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence
9.5%Open-label Extension Phase B/F/TAF
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
5.3%DB STB to OL STB
NCT01705574 · Phase 3 · registry result, not featured evidence
8.7%Double-Blind: STB
NCT01705574 · Phase 3 · registry result, not featured evidence
9.1%
NCT02616783 · Phase 3 · registry result, not featured evidence
4.5%Delayed E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
6.6%E/C/F/TAF
NCT02605954 · Phase 3 · registry result, not featured evidence
9.5%E/C/F/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
16.2%F/R/TAF + LDV/SOF
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
10.7%Part 1 Randomized Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
0%Part 1 Sentinel Cohort TAF
NCT01967940 · Phase 3 · registry result, not featured evidence
10.8%Part 2 E/C/F/TAF + ATV
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
16.2%HIV-Suppressed
NCT02071082 · Phase 3 · registry result, not featured evidence
0%HIV/HBV Treatment-Naive
NCT02071082 · Phase 3 · registry result, not featured evidence
4.8%Cohort 1: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
10.1%Cohort 2: E/C/F/TAF+DRV
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
6%E/C/F/TAF (12 - 17 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
0%E/C/F/TAF (≥ 18 Years of Age)
NCT02276612 · Phase 2/3 · registry result, not featured evidence
7.7%Group 1: SC LEN+(F/TAF→ TAF)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
7.5%Group 2: SC LEN + (F/TAF → BIC)
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
13.5%Group 3: Oral LEN + F/TAF
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
—BIC + F/TAF
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
6.2%BIC + F/TAF (Double-Blind Randomiz
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
10.7%
NCT01497899 · Phase 2 · registry result, not featured evidence
4.9%
NCT01565850 · Phase 2 · registry result, not featured evidence
18.2%
NCT03960645 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
i
injection site discomfort 13.6%
injection site pain 13.6%
fatigue 2.3%
NCT04982445 · Phase 4 · registry result, not featured evidence
show 40 more results
400 mg + 600 mg Q4W
injection site pain 32.3%
injection site nodule 9.7%
injection site induration 2.2%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 74.2%
injection site nodule 64.5%
injection site erythema 51.6%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
400 mg + 600 mg Q4W
injection site pain 30.9%
injection site nodule 3.2%
injection site pruritus 2.1%
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
injection site pain 65.2%
covid-19 17.9%
headache 12.5%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 60.6%
covid-19 19.4%
injection site induration 11.4%
NCT04542070 · Phase 3 · registry result, not featured evidence
Q2M
injection site pain 37.9%
covid-19 14.5%
arthralgia 0%
NCT04542070 · Phase 3 · registry result, not featured evidence
injection site pain 80.2%
covid-19 18.4%
injection site induration 11.2%
NCT04399551 · Phase 3 · registry result, not featured evidence
injection site pain 55.7%
injection site discomfort 26.1%
fatigue 20%
NCT04001803 · Phase 3 · registry result, not featured evidence
creatinine renal clearance decreased 19.7%
lipase increased 11.3%
chills 7%
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 99.1%
injection site nodule 49.6%
nasopharyngitis 47%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q4W
injection site pain 80%
injection site nodule 50%
nasopharyngitis 50%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 96.5%
nasopharyngitis 47%
injection site nodule 40%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
IM-Q8W
injection site pain 91.2%
injection site nodule 35.3%
covid-19 26.5%
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
Q2M
injection site pain 74.4%
covid-19 33.3%
upper respiratory tract infection 17.8%
NCT03639311 · Phase 2 · registry result, not featured evidence · combination
30 mg
headache 21.7%
nausea 18.3%
upper respiratory tract infection 13.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 26.4%
diarrhoea 13.2%
rash 11.3%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 31.9%
back pain 12.8%
oropharyngeal pain 12.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
headache 21.3%
diarrhoea 18%
nausea 18%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 21.8%
nausea 14.5%
bronchitis 10.9%
NCT01641809 · Phase 2 · registry result, not featured evidence
60 mg
upper respiratory tract infection 27.5%
anxiety 11.8%
sinusitis 11.8%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
nausea 23.3%
headache 21.7%
diarrhoea 16.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
upper respiratory tract infection 17.3%
depression 9.6%
diarrhoea 9.6%
NCT01641809 · Phase 2 · registry result, not featured evidence
10 mg
diarrhoea 13%
nasopharyngitis 10.9%
gonorrhoea 8.7%
NCT01641809 · Phase 2 · registry result, not featured evidence
30 mg
dizziness 37.5% (placebo 0%)
dyspepsia 25% (placebo 0%)
headache 25% (placebo 0%)
NCT00920426 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain 0% (placebo 0%)
abnormal dreams 0% (placebo 0%)
blood bilirubin increased 0% (placebo 50%)
NCT00920426 · Phase 2 · registry result, not featured evidence
30 mg
atrioventricular block first degree 7.7%
decreased appetite 7.7%
headache 7.7%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
aspartate aminotransferase increased 50%
blood creatine phosphokinase increased 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site nodule 55.6%
injection site erythema 44.4%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site haemorrhage 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 72.7%
injection site pain 72.7%
injection site induration 45.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site induration 100%
injection site pain 100%
injection site bruising 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 75%
headache 37.5%
injection site swelling 37.5%
NCT04484337 · Phase 1 · registry result, not featured evidence
catheter site bruise 50%
injection site erythema 50%
injection site induration 50%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 94.4%
headache 77.8%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site erythema 100%
injection site pain 100%
injection site pruritus 87.5%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
injection site erythema 100%
injection site pain 100%
injection site warmth 88.9%
NCT04484337 · Phase 1 · registry result, not featured evidence · combination
accident 100%
injection site nodule 100%
injection site pain 100%
NCT04484337 · Phase 1 · registry result, not featured evidence
injection site pain 100%
injection site swelling 70%
headache 60%
NCT04484337 · Phase 1 · registry result, not featured evidence
30 mg
blood creatine phosphokinase increased 6.7%
contusion 6.7%
body temperature increased 0%
NCT03149848 · Phase 1 · registry result, not featured evidence
300 mg + 30 mg
body temperature increased 7.1%
headache 7.1%
hyperkeratosis 7.1%
NCT03149848 · Phase 1 · registry result, not featured evidence · combination
j
upper respiratory tract infection 16.2%
diarrhoea 13.2%
nasopharyngitis 12.9%
NCT02121795 · Phase 3 · combination
show 45 more results
nasopharyngitis 12.1%
back pain 9.1%
syphilis 9.1%
NCT02121795 · Phase 3
onychomycosis 9.7%
sinusitis 9.7%
arthralgia 6.5%
NCT02121795 · Phase 3
nasopharyngitis 20.4%
upper respiratory tract infection 12.9%
cough 12.1%
NCT02469246 · Phase 3
nasopharyngitis 20%
renal colic 20%
rhinitis 20%
NCT02469246 · Phase 3
spinal pain 16.7%
arthralgia 0%
back pain 0%
NCT02469246 · Phase 3
diarrhoea 23%
headache 22.7%
upper respiratory tract infection 20.2%
NCT01797445 · Phase 3
nasopharyngitis 3.5%
headache 2.8%
arthralgia 1.4%
NCT01797445 · Phase 3
nasopharyngitis 4.2%
cough 2.5%
syphilis 2.5%
NCT01797445 · Phase 3
upper respiratory tract infection 7.4%
nasopharyngitis 5.2%
diarrhoea 4.4%
NCT01815736 · Phase 3
upper respiratory tract infection 6.1%
diarrhoea 5.2%
nasopharyngitis 4.7%
NCT01815736 · Phase 3
upper respiratory tract infection 17.5%
diarrhoea 11.4%
nasopharyngitis 10%
NCT01815736 · Phase 3
upper respiratory tract infection 16.1%
bronchitis 15.3%
arthralgia 14%
NCT01818596 · Phase 3
hyperlipidaemia 33.3%
pain in extremity 33.3%
anogenital warts 16.7%
NCT01818596 · Phase 3
upper respiratory tract infection 40%
respiratory tract infection 38%
nausea 30%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
upper respiratory tract infection 26.9%
vomiting 25%
respiratory tract infection 21.2%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
upper respiratory tract infection 51.9%
cough 33.3%
nasopharyngitis 18.5%
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
diarrhoea 20.6%
headache 17.8%
nasopharyngitis 15.9%
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
diarrhoea 17.2%
upper respiratory tract infection 14.6%
headache 14%
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
syphilis 8.7%
covid-19 7.9%
nasopharyngitis 7.1%
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
nasopharyngitis 15.5%
upper respiratory tract infection 11.6%
diarrhoea 9.2%
NCT03110380 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 7.2%
arthralgia 3.2%
bronchitis 3.2%
NCT03110380 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 8.6%
diarrhoea 6%
fatigue 6%
NCT03110380 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 14.6%
headache 11%
anaemia 7.3%
NCT01705574 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 17.3%
headache 17%
nausea 14.9%
NCT01705574 · Phase 3 · registry result, not featured evidence
nasopharyngitis 10.9%
back pain 8.2%
diarrhoea 7.3%
NCT02616783 · Phase 3 · registry result, not featured evidence
arthralgia 9%
diarrhoea 4.5%
headache 4.5%
NCT02605954 · Phase 3 · registry result, not featured evidence
diarrhoea 10.4%
headache 8.2%
vitamin d deficiency 7.1%
NCT02605954 · Phase 3 · registry result, not featured evidence
urinary tract infection 13.5%
upper respiratory tract infection 12.2%
arthralgia 9.5%
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
cough 13.5%
headache 10.8%
nausea 8.1%
NCT02707601 · Phase 3 · registry result, not featured evidence · combination
hyperbilirubinaemia 3.6% (placebo 0%)
influenza 3.6% (placebo 0%)
jaundice 3.6% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence
nausea 16.7% (placebo 0%)
arthralgia 8.3% (placebo 0%)
diarrhoea 8.3% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence
upper respiratory tract infection 29.7% (placebo 0%)
malaria 13.5% (placebo 0%)
headache 10.8% (placebo 0%)
NCT01967940 · Phase 3 · registry result, not featured evidence · combination
upper respiratory tract infection 23%
nasopharyngitis 12.2%
diarrhoea 10.8%
NCT02071082 · Phase 3 · registry result, not featured evidence
dental caries 33.3%
diarrhoea 33.3%
herpes zoster 33.3%
NCT02071082 · Phase 3 · registry result, not featured evidence
acute sinusitis 19%
bronchitis 14.3%
sinusitis 14.3%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
back pain 12.4%
upper respiratory tract infection 11.2%
bronchitis 6.7%
NCT01968551 · Phase 3 · registry result, not featured evidence · combination
cough 24%
upper respiratory tract infection 22%
vomiting 16%
NCT02276612 · Phase 2/3 · registry result, not featured evidence
upper respiratory tract infection 60%
cough 50%
nasal obstruction 30%
NCT02276612 · Phase 2/3 · registry result, not featured evidence
injection site erythema 48.1%
injection site swelling 32.7%
injection site pain 28.8%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
injection site erythema 34%
injection site swelling 34%
injection site pain 26.4%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
covid-19 21.2%
influenza 21.2%
headache 17.3%
NCT04143594 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 13.8%
upper respiratory tract infection 10.8%
headache 9.2%
NCT02397694 · Phase 2 · registry result, not featured evidence · combination
nausea 22.3%
diarrhoea 17%
fatigue 16.1%
NCT01497899 · Phase 2 · registry result, not featured evidence
diarrhoea 21.4%
upper respiratory tract infection 15.5%
fatigue 13.6%
NCT01565850 · Phase 2 · registry result, not featured evidence
back pain 12.1%
gestational diabetes 12.1%
anaemia 9.1%
NCT03960645 · Phase 1 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bTrial phases differ: Phase 2 versus Phase 2/3.
  3. cPopulation comparability has not been reviewed for both studies.
  4. dTreatment context differs: pooled versus combination.
  5. eAssessment timepoints differ: 324 weeks versus 48 weeks.
  6. fTrial phases differ: Phase 2 versus Phase 3.
  7. gTreatment context has not been resolved for both arms.
  8. hAssessment timepoints differ: 52 weeks versus 144 weeks.
  9. iPopulation comparability has not been reviewed for these studies.
  10. jPopulation comparability has not been reviewed for 47 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Cabotegravir/rilpivirine (Cabenuva)

HIV-1 RNA Less Than 50 Copies Per 100% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
99% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
90% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
HIV-1 RNA Ge50 Copies 0% (n=93) @ 4wk400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 2 more results
1.1% (n=93) @ 8wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
2.2% (n=93) @ 12wk400 mg + 600 mg Q4W
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
Virologic Failure 0% (n=93)400 mg + 600 mg Q4W
responder rate · % of participants
No placebo or comparator arm
NCT05896748 · Phase 3 · registry result, not featured evidence · combination
show 1 more result
0% (n=115)
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0% (n=430) @ 4.33wk
event count · % of participants
No placebo or comparator arm
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
show 6 more results
0% (n=430) @ 8.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 17.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 26wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0% (n=430) @ 34.67wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
0.2% (n=430) @ 43.33wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted
0% (n=430) @ 52wk*
NCT04399551 · Phase 3 · registry result, not featured evidence · converted to % from 0 Participants as posted
HIV-1 RNA LT 50 Copies 93.9% (n=115) @ 4.33wk
responder rate · % of participants
No placebo or comparator arm
NCT04001803 · Phase 3 · registry result, not featured evidence
show 25 more results
94.8% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
91.3% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
90.4% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
87.8% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
88.7% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
96% (n=115) @ 4.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 8.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
98% (n=115) @ 17.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 26wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 34.67wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 43.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 52wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 56.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 65wk
NCT04001803 · Phase 3 · registry result, not featured evidence
99% (n=115) @ 69.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 78wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 82.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 91wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 95.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 104wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 108.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 117wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 121.33wk
NCT04001803 · Phase 3 · registry result, not featured evidence
100% (n=115) @ 130wk
NCT04001803 · Phase 3 · registry result, not featured evidence
Virologic Failure 0.07 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.04 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Treatment Failure 0.14 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.2 Cumulative probability @ 44wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 0.13 Cumulative probability @ 44wk
absolute value · Cumulative probability
No placebo or comparator arm
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
0.12 Cumulative probability @ 24wk
NCT03739996 · Phase 2 · registry result, not featured evidence · combination
Virologic Failure Rate 50 9.9% (n=71) @ 44wk
event count · % of participants
No placebo or comparator arm
HIV-1 RNA ≥ 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 7 Participants as posted
Virologic Response 50 Copies Snapshot 81.7% (n=71) @ 44wk
responder rate · % of participants
No placebo or comparator arm
HIV-1 RNA < 50 copies/mL on treatment
NCT03739996 · Phase 2 · registry result, not featured evidence · combination · converted to % from 58 Participants as posted
Virologic Failure 0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wkIM-Q4W
event count · % of participants
Maintenance
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
show 6 more results
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q4W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 0 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
0.9% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 32wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
1.7% (n=115) vs 1.8% (n=56) CAB 30 mg+ABC/3TC @ 48wk*IM-Q8W
NCT02120352 · Phase 2 · registry result, not featured evidence · combination · converted to % from 2 Participants as posted
1.1% (n=90) vs 0% (n=7) DTG + RPV*Q2M
NCT03639311 · Phase 2 · registry result, not featured evidence · combination · converted to % from 1 Participants as posted
HIV-1 RNA Less Than 50 Copies 99% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q4W
responder rate · % of participants
Maintenance
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
95% (n=115) vs 98% (n=56) CAB 30 mg+ABC/3TC @ 0wkIM-Q8W
HIV-1 RNA<50 c/mL, Day 1
NCT02120352 · Phase 2 · registry result, not featured evidence · combination

+ 163 further endpoints in the CSV export.

Tenofovir alafenamide/emtricitabine

HIV-1 RNA Less Than 20 Copies 91.6% (n=333) vs 90.9% (n=330) FTC/TDF @ 48wk
responder rate · % of participants
Maintenance
NCT02121795 · Phase 3 · combination
show 6 more results
83.5% (n=333) vs 86.1% (n=330) FTC/TDF @ 96wk
NCT02121795 · Phase 3 · combination
85.7% (n=280) vs 87.3% (n=276) ABC/3TC @ 48wk
NCT02469246 · Phase 3
80.4% (n=280) vs 86.2% (n=276) ABC/3TC @ 96wk
NCT02469246 · Phase 3
82.4% (n=431) vs 80.7% (n=435) E/C/F/TDF @ 48wk
NCT01797445 · Phase 3
78.7% (n=431) vs 76.8% (n=435) E/C/F/TDF @ 96wk
NCT01797445 · Phase 3
90.6% (n=959) vs 85.3% (n=477) Baseline Treatment Regimen (SBR) @ 96wk
NCT01815736 · Phase 3
HIV-1 RNA Less Than 50 Copies 97.2% (n=959) vs 93.1% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
Maintenance
All Participants
NCT01815736 · Phase 3
HIV-1 RNA Less Than 20 Copies 93.5% (n=959) vs 90.4% (n=477) Baseline Treatment Regimen (SBR) @ 48wk
responder rate · % of participants
Maintenance
All Participants
NCT01815736 · Phase 3
HIV-1 RNA Less 400 94% (n=50) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 9 more results
94% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
94% (n=50) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
94% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
97.9% (n=48) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
97.9% (n=48) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
100% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV-1 RNA -3.25 copies/mL @ 24wk
absolute change · copies/mL
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 1 more result
-3.26 copies/mL @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
CD4+ 7.7% (n=50) @ 24wk
absolute change · percentage points
No placebo or comparator arm
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
show 5 more results
9.3% (n=50) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-0.8% (n=52) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
-0.6% (n=52) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0% (n=27) @ 24wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
0.2% (n=27) @ 48wk
NCT01854775 · Phase 2/3 · combination · HIV · phase 2/3
HIV RNA Less Than 50 Copies 89.4% (n=320) vs 92.9% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
Maintenance
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 2 more results
84.1% (n=320) vs 86.5% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
81.9% (n=320) vs 84% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
HIV-1 RNA Less Than 20 82.2% (n=320) vs 87.1% (n=325) DTG + F/TAF @ 48wk
responder rate · % of participants
Maintenance
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 5 more results
77.5% (n=320) vs 80.3% (n=325) DTG + F/TAF @ 96wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
77.5% (n=320) vs 79.1% (n=325) DTG + F/TAF @ 144wk
NCT02607956 · Phase 3 · registry result, not featured evidence · HIV · phase 3
87.6% (n=314) vs 87.3% (n=315) ABC/DTG/3TC @ 48wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
83.4% (n=314) vs 84.8% (n=315) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
78% (n=314) vs 82.2% (n=315) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
Hip BMD -0.802% (n=278) vs -1.148% (n=281) ABC/DTG/3TC @ 48wk
percent change · % of baseline
Maintenance
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 4 more results
-1.128% (n=250) vs -1.262% (n=257) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-1.02% (n=236) vs -1.291% (n=240) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
1.33% (n=101) vs -0.726% (n=54) Stay on Baseline Regimen @ 48wk
NCT02616783 · Phase 3 · registry result, not featured evidence
0.808% (n=103) vs -0.537% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence
Spine BMD -0.772% (n=284) vs -0.552% (n=285) ABC/DTG/3TC @ 48wk
percent change · % of baseline
Maintenance
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
show 2 more results
-0.705% (n=256) vs -0.219% (n=258) ABC/DTG/3TC @ 96wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
-0.371% (n=243) vs 0.035% (n=244) ABC/DTG/3TC @ 144wk
NCT02607930 · Phase 3 · registry result, not featured evidence · HIV · phase 3
CD4+ 265 vs 35 GEN cells/uL
absolute change · cells/uL
Extension (open-label)
NCT01705574 · Phase 3 · registry result, not featured evidence
Lumbar Spine BMD 2.237% (n=102) vs -0.104% (n=54) Stay on Baseline Regimen @ 48wk
percent change · % of baseline
Maintenance
NCT02616783 · Phase 3 · registry result, not featured evidence
show 1 more result
1.625% (n=104) vs -0.027% (n=54) Stay on Baseline Regimen @ 24wk
NCT02616783 · Phase 3 · registry result, not featured evidence

+ 14 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Cabotegravir/rilpivirine (Cabenuva)'s landscape · Tenofovir alafenamide/emtricitabine's landscape